A new paradigm for local and sustained release of therapeutic molecules to the injured spinal cord for neuroprotection and tissue repair

Tissue Engineering - Part A

Volumn 15, Issue 3, 2009, Pages 595-604

  Kang, Catherine E ^a,b   Poon, Peter C ^a   Tator, Charles H ^a   Shoichet, Molly S ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MATERIALS; CELL DEATH; CELL MEMBRANES; DISSOLUTION; DOSIMETRY; DRUG DELIVERY; GELATION; HYDROXYLATION; LABELS; MOLECULES; SEMICONDUCTOR COUNTERS;

DELIVERY SYSTEMS; DRUG DELIVERY SYSTEM; FLUORESCENT LABELS; HYALURONAN; IN-VITRO; IN-VIVO; INJURED SPINAL CORDS; INJURY MODELS; INTRAPERITONEAL; INTRATHECAL; LOCAL DELIVERY; METHYLCELLULOSE; NEUROPROTECTION; NEW SYSTEM; SPINAL CORD INJURY; SPINAL CORDS; SUSTAINED RELEASE; THERAPEUTIC BENEFITS; THERAPEUTIC EFFECTS; THERAPEUTIC MOLECULES; TISSUE LOSS; TISSUE REPAIR;

MEATS;

ERYTHROPOIETIN; FLUORESCENT DYE; HYALURONIC ACID; METHYLCELLULOSE; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; GEL; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INJURY SEVERITY; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SAFETY; SPINAL CORD INJURY; SUSTAINED DRUG RELEASE; TISSUE REPAIR; ANIMAL; DELAYED RELEASE FORMULATION; DRUG EFFECT; METABOLISM; SPRAGUE DAWLEY RAT; WOUND HEALING;

ANIMALS; CELL COUNT; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; ERYTHROPOIETIN; HYALURONIC ACID; METHYLCELLULOSE; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD INJURIES; WOUND HEALING;

EID: 64549091117     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2007.0349     Document Type: Article

References (54)

1. Tator, C.H. Review of treatment trials in human spinal cord injury: issues, difficulties, and recommendations. Neurosurgery 59(5), 957-982, 2006; discussion 982--987.
2. Hall, E.D., and Springer, J.E. Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRx 1(1), 80-100, 2004.
3. Terada, H., Kazui, T., Takinami, M., Yamashita, K., Washiyama, N., and Muhammad, B.A. Reduction of ischemic spinal cord injury by dextrorphan: comparison of several methods of administration. J Thorac Cardiovasc Surg 122(5), 979-985, 2001.
4. Yaksh, T.L., Horais, K.A., Tozier, N., Rathbun, M., Richter, P., Rossi, S., Grafe, M., Tong, C., Meschter, C., Cline, J.M., and Eisenach, J. Intrathecal ketorolac in dogs and rats. Toxicol Sci 80(2), 322-334, 2004.
5. Reynolds, L., Rauck, R., Webster, L., DuPen, S., Heinze, E., Portenoy, R., Katz, N., Charapata, S., Wallace, M., and Fisher, D.M. Relative analgesic potency of fentanyl and sufentanil during intermediate-term infusions in patients after long-term opioid treatment for chronic pain. Pain 110(1-2), 182-188, 2004.
6. Jones, L.L., and Tuszynski, M.H. Chronic intrathecal infusions after spinal cord injury cause scarring and compression. Microsc Res Tech 54(5), 317-324, 2001.
7. Jimenez Hamann, M.C., Tator, C.H., and Shoichet, M.S. Injectable intrathecal delivery system for localized administration of EGF and FGF-2 to the injured rat spinal cord. Exp Neurol 194(1), 106-119, 2005.
8. Jimenez Hamann, M.C., Tsai, E.C., Tator, C.H., and Shoichet, M.S. Novel intrathecal delivery system for treatment of spinal cord injury. Exp Neurol 182(2), 300-309, 2003.
9. Gupta, D., Tator, C.H., and Shoichet, M.S. Fast-gelling injectable blend of hyaluronan and methylcellulose for intrathecal, localized delivery to the injured spinal cord. Biomaterials 27(11), 2370-2379, 2006.
10. Constantini, S., and Young, W. The effects of methylprednisolone and the ganglioside GM1 on acute spinal cord injury in rats. J Neurosurg 80(1), 97-111, 1994.
11. Fehlings, M.G. Editorial: recommendations regarding the use of methylprednisolone in acute spinal cord injury: making sense outof the controversy. Spine26(24 Suppl), S56-S57, 2001.
12. Hurlbert, R.J. The role of steroids in acute spinal cord injury: an evidence-based analysis. Spine 26(24 Suppl), S39-S46, 2001.
13. Celik, M., Gokmen, N., Erbayraktar, S., Akhisaroglu, M., Konakc, S., Ulukus, C., Genc, S., Genc, K., Sagiroglu, E., Cerami, A., and Brines, M. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA 99(4), 2258-2263, 2002.
14. Ray, S.K., Matzelle, D.D., Sribnick, E.A., Guyton, M.K., Wingrave, J.M., and Banik, N.L. Calpain inhibitor prevented apoptosis and maintained transcription of proteolipid protein and myelin basic protein genes in rat spinal cord injury. J Chem Neuroanat 26(2), 119-124, 2003.
15. Kigerl, K.A., Lai, W., Rivest, S., Hart, R.P., Satoskar, A.R., and Popovich, P.G. Toll-like receptor (TLR)-2 and TLR-4 regulate inflammation, gliosis, and myelin sparing after spinal cord injury. J Neurochem 102(1), 37-50, 2007.
16. Tamura, M., Nakamura, M., Ogawa, Y., Toyama, Y., Miura, M., and Okano, H. Targeted expression of anti-apoptotic protein p35 in oligodendrocytes reduces delayed demyelination and functional impairment after spinal cord injury. Glia 51(4), 312-321, 2005.
17. Qiao, F., Atkinson, C., Song, H., Pannu, R., Singh, I., and Tomlinson, S. Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am J Pathol 169(3), 1039-1047, 2006.
18. Pannu, R., and Singh, I. Pharmacological strategies for the regulation of inducible nitric oxide synthase: neurodegenerative versus neuroprotective mechanisms. Neurochem Int 49(2), 170-182, 2006.
19. Bernaudin, M., Marti, H.H., Roussel, S., Divoux, D., Nouvelot, A., MacKenzie, E.T., and Petit, E. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 19(6), 643-651, 1999.
20. Siren, A.L., Knerlich, F., Poser, W., Gleiter, C.H., Bruck, W., and Ehrenreich, H. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol 101(3), 271-276, 2001.
21. Demers, E.J., McPherson, R.J., and Juul, S.E. Erythropoietin protects dopaminergic neurons and improves neurobehavioral outcomes in juvenile rats after neonatal hypoxiaischemia. Pediatr Res 58(2), 297-301, 2005.
22. Aydin, A., Genc, K., Akhisaroglu, M., Yorukoglu, K., Gokmen, N., and Gonullu, E. Erythropoietin exerts neuroprotective effect in neonatal rat model of hypoxic-ischemic brain injury. Brain Dev 25(7), 494-498, 2003.
23. Ehrenreich, H., Hasselblatt, M., Dembowski, C., Cepek, L., Lewczuk, P., Stiefel, M., Rustenbeck, H.H., Breiter, N., Jacob, S., Knerlich, F., Bohn, M., Poser, W., Ruther, E., Kochen, M., Gefeller, O., Gleiter, C., Wessel, T.C., De Ryck, M., Itri, L., Prange, H., Cerami, A., Brines, M., and Siren, A.L. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8(8), 495-505, 2002.
24. Grasso, G., Sfacteria, A., Meli, F., Fodale, V., Buemi, M., and Iacopino, D.G. Neuroprotection by erythropoietin administration after experimental traumatic brain injury. Brain Res 1182, 99-105, 2007.
25. Gorio, A., Gokmen, N., Erbayraktar, S., Yilmaz, O., Madaschi, L., Cichetti, C., Di Giulio, A.M., Vardar, E., Cerami, A., and Brines, M. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA 99(14), 9450-9455, 2002.
26. Kaptanoglu, E., Solaroglu, I., Okutan, O., Surucu, H.S., Akbiyik, F., and Beskonakli, E. Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings. Neurosurg Rev 27(2), 113-120, 2004.
27. Agnello, D., Bigini, P., Villa, P., Mennini, T., Cerami, A., Brines, M.L., and Ghezzi, P. Erythropoietin exerts an antiinflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 952(1), 128-134, 2002.
28. Villa, P., Bigini, P., Mennini, T., Agnello, D., Laragione, T., Cagnotto, A., Viviani, B., Marinovich, M., Cerami, A., Coleman, T.R., Brines, M., and Ghezzi, P. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 198(6), 971-975, 2003.
29. Diaz, Z., Assaraf, M.I., Miller, W.H., Jr., and Schipper, H.M. Astroglial cytoprotection by erythropoietin preconditioning: implications for ischemic and degenerative CNS disorders. J Neurochem 93(2), 392-402, 2005.
30. Sugawa, M., Sakurai, Y., Ishikawa-Ieda, Y., Suzuki, H., and Asou, H. Effects of erythropoietin on glial cell development; oligodendrocyte maturation and astrocyte proliferation. Neurosci Res 44(4), 391-403, 2002.
31. Konishi, Y., Chui, D.H., Hirose, H., Kunishita, T., and Tabira, T. Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res 609(1-2), 29-35, 1993.
32. Masuda, S., Okano, M., Yamagishi, K., Nagao, M., Ueda, M., and Sasaki, R. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 269(30), 19488-19493, 1994.
33. Brines, M.L., Ghezzi, P., Keenan, S., Agnello, D., de Lanerolle, N.C., Cerami, C., Itri, L.M., and Cerami, A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97(19), 10526-10531, 2000.
34. Prestwich, G.D., Marecak, D.M., Marecek, J.F., Vercruysse, K.P., and Ziebell, M.R. Controlled chemical modification of hyaluronic acid: synthesis, applications, and biodegradation of hydrazide derivatives. J Control Release 53(1-3), 93-103, 1998.
35. Hermanson, G. Bioconjugate Techniques. Second edition, San Diego, CA: Academic Press, 1996.
36. Rivlin, A.S., and Tator, C.H. Effect of duration of acute spinal cord compression in a new acute cord injury model in the rat. Surg Neurol 10(1), 38-43, 1978.
37. Basso, D.M., Beattie, M.S., and Bresnahan, J.C. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 12(1), 1-21, 1995.
38. Poon, P.C., Gupta, D., Shoichet, M.S., and Tator, C.H. Clip compression model is useful for thoracic spinal cord injuries: histologic and functional correlates. Spine 32(25), 2853-2859, 2007.
39. Ritger, P.L., and Peppas, N.A. A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Control Release 5(1), 23-36, 1987.
40. Narasimhan, B., and Peppas, N.A. Molecular analysis of drug delivery systems controlled by dissolution of the polymer carrier. J Pharm Sci 86(3), 297-304, 1997.
41. Kwon, B.K., Tetzlaff, W., Grauer, J.N., Beiner, J., and Vaccaro, A.R. Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J 4(4), 451-464, 2004.
42. Carlson, G.D., and Gorden, C. Current developments in spinal cord injury research. Spine J 2(2), 116-128, 2002.
43. Belazs, E. Medical applications of hyaluronan and its derivatives. In: Gebelein, C., ed. Cosmetic and Pharmaceutical Applications of Polymers. New York: Plenum Press, 293-310, 1991.
44. Mann, C., Lee, J.H., Liu, J., Stammers, A.M., Sohn, H.M., Tetzlaff, W., and Kwon, B.K. Delayed treatment of spinal cord injury with erythropoietin or darbepoetin-a lack of neuroprotective efficacy in a contusion model of cord injury. Exp Neurol 211(1), 34-40, 2008.
45. Deen, W. Analysis of transport phenomena. In: Gubbins, K.E., ed. Topics in Chemical Engineering. New York: Oxford University Press, 86-91, 1998.
46. Stroh, M., Zipfel, W.R., Williams, R.M., Webb, W.W., and Saltzman, W.M. Diffusion of nerve growth factor in rat striatum as determined by multiphoton microscopy. Biophys J 85(1), 581-588, 2003.
47. Loth, F., Yardimci, M.A., and Alperin, N. Hydrodynamic modeling of cerebrospinal fluid motion within the spinal cavity. J Biomech Eng 123(1), 71-79, 2001.
48. Delpech, B., Bertrand, P., and Chauzy, C. An indirect enzymoimmunological assay for hyaluronidase. J Immunol Methods 104(1-2), 223-229, 1987.
49. Laurent, U.B., Laurent, T.C., Hellsing, L.K., Persson, L., Hartman, M., and Lilja, K. Hyaluronan in human cerebrospinal fluid. Acta Neurol Scand 94(3), 194-206, 1996.
50. Stohlman, Jr., F., Ebbe, S., Morse, B., Howard, D., and Donovan, J. Regulation of erythropoiesis. XX. Kinetics of red cell production. Ann NY Acad Sci 149(1), 156-172, 1968.
51. Morishita, E., Masuda, S., Nagao, M., Yasuda, Y., and Sasaki, R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 76(1), 105-116, 1997.
52. Yalcin, M., Ak, F., Cangul, I.T., and Erturk, M. The effect of centrally administered erythropoietin on cardiovascular and respiratory system of anaesthetized rats. Auton Neurosci 134(1-2), 1-7, 2007.
53. Chen, G., Shi, J.X., Hang, C.H., Xie, W., Liu, J., and Liu, X. Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: a potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO). Neurosci Lett 425(3), 177-182, 2007.
54. Yatsiv, I., Grigoriadis, N., Simeonidou, C., Stahel, P.F., Schmidt, O.I., Alexandrovitch, A.G., Tsenter, J., and Shohami, E. Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J 19(12), 1701-1703, 2005.